InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,178.00
(
1.88%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.85
(
0.26%
)
Bitcoin
59,604.51
(
0.82%
)
Post# of 251692
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119554
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 208653

Monday, 02/13/2017 4:13:29 PM

Monday, February 13, 2017 4:13:29 PM

Post# of 251692
AVIR—Vapendavir for rhinovirus fails phase-2b:

http://finance.yahoo.com/news/aviragen-therapeutics-announces-top-line-210100346.html

Aviragen Therapeutics…today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.

This is AVIR’s second clinical failure in the past two weeks—the first was a phase-2 trial in RSV (#msg-128351130).

The stock appears to be halted.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up